Kishimoto S, Fujimura J, Machino H, Shimamoto T, Kobayashi H, Shimizu S, Haruma K, Kajiyama G, Sakurai K, Yamasaki K
Department of Medicine, Hiroshima University School of Medicine, Japan.
Res Commun Chem Pathol Pharmacol. 1992 Dec;78(3):259-77.
The present study evaluated the therapeutic effects of rebamipide alone and in combination with cimetidine on experimental gastritis established by the administration of 5 mM sodium taurocholate (TCA) for 6 months in rats. Morphological and biochemical analyses were performed to determine the effects of rebamipide, administered alone or in combination with cimetidine, on chronic, atrophic and erosive gastritis. Rebamipide and cimetidine were administered to rats as a dietary admixture for 4 weeks after withdrawal of TCA. Rebamipide dose-dependently reduced the total length of the erosion, normalized the mucosal thickness and increased the number of parietal and total cells, and tended to reduce interstitial infiltration of inflammatory cells and proliferation of collagenous fibers. Moreover, histochemical and biochemical studies also showed rebamipide to be effective. Rebamipide increased the PAS-positive mucus and normalized the reduced gastric mucosal SOD activity. The therapeutic effect of rebamipide on the experimental gastritis was enhanced by the combined use of cimetidine. These results suggest that rebamipide has a therapeutic effect on chronic atrophic erosive gastritis induced by TCA, and that the mechanism of the therapeutic effect is partially due to the increase in PAS-positive mucus and gastric mucosal SOD activity. Furthermore, the enhanced effect of the combination therapy of rebamipide with cimetidine was considered to be due to the actions of both cimetidine and rebamipide.
本研究评估了瑞巴派特单独使用以及与西咪替丁联合使用对大鼠实验性胃炎的治疗效果。该实验性胃炎通过给大鼠连续6个月灌胃5 mM牛磺胆酸钠(TCA)建立。进行了形态学和生化分析,以确定单独使用或与西咪替丁联合使用瑞巴派特对慢性、萎缩性和糜烂性胃炎的影响。在停用TCA后,将瑞巴派特和西咪替丁作为饮食添加剂给予大鼠4周。瑞巴派特剂量依赖性地缩短了糜烂的总长度,使黏膜厚度恢复正常,增加了壁细胞和总细胞的数量,并倾向于减少炎性细胞的间质浸润和胶原纤维的增殖。此外,组织化学和生化研究也表明瑞巴派特是有效的。瑞巴派特增加了PAS阳性黏液,并使降低的胃黏膜超氧化物歧化酶(SOD)活性恢复正常。西咪替丁与瑞巴派特联合使用增强了瑞巴派特对实验性胃炎的治疗效果。这些结果表明,瑞巴派特对TCA诱导的慢性萎缩性糜烂性胃炎具有治疗作用,其治疗作用机制部分归因于PAS阳性黏液和胃黏膜SOD活性的增加。此外,瑞巴派特与西咪替丁联合治疗效果增强被认为是由于西咪替丁和瑞巴派特二者的作用。